ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 10

Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score

Flavio Signorelli1, Gustavo G M Balbi2, Roger A. Levy2 and Savino Sciascia3, 1Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antiphospholipid antibodies, Antiphospholipid syndrome and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The adjusted Global AntiPhospholipid Syndrome Score (aGAPSS) was described as a tool to estimate the risk of thromboses in patients with APS. The aim of this study is to evaluate if higher values of aGAPSS correlate with the presence of arterial or venous thromboses in thrombotic primary APS patients.

Methods: A cross-sectional study was performed in a group of 72 outpatients who fulfilled thrombotic pAPS classification criteria (Sydney). Clinical and serologic features were collected during visits and by chart review. aGAPSS was calculated for each patient and correlated to arterial and venous thromboses. Statistical analysis was performed using chi-square, Mann-Whitney U and Spearman’s R when applicable. Multivariate regression analysis included age, sex, race and variables with p<0.10 in the bivariate analysis.

Results: Thirty-seven (51.4%) patients had arterial events and 51 (70.8%) had venous thromboses. The mean number of episodes of arterial and venous thromboses was 1.65 and 1.4 per patient, respectively. The median aGAPSS of the 72 patients included in the analysis was 9 (7-13); this was used to divide two groups of patients: low aGAPSS (<10) and high aGAPSS (≥10). Patients with or without arterial thromboses were compared regarding the presence of high aGAPSS. In a bivariate analysis, higher aGAPSS correlated with the presence of arterial thromboses (p=0.018). In a multivariate regression analysis, higher aGAPSS remained as a risk factor for the presence of arterial thromboses (OR 3.4, 95%CI 1.26-9.2, p=0.016). Demographic and clinical characteristics of this group of patients are shown in Table 1. Regarding venous thrombosis, there was a tendency towards higher levels of aGAPSS (p=0.063). To avoid contamination of data, a new different analysis was performed. Patients who presented both arterial and venous thromboses were excluded, and 2 groups were created, one with arterial exclusive events (N=19) and another with venous exclusive events (N=35). The group with arterial exclusive thromboses had higher values of aGAPSS (p=0.007). In the multivariate analysis, high aGAPSS was associated with increased risk of arterial events (OR 4.95, 95%CI 1.49-16.47). Patients with both arterial and venous thromboses did not have higher aGAPSS (p=0.677).

Conclusion: The presence of arterial events was associated with higher values of aGAPSS. aGAPSS seems to be a tool capable to detect high risk thrombotic patients, particularly arterial events.

Table 1: Demographic and clinical characteristics (N=72).

Variable

Arterial thromboses (N=37)

No arterial thromboses (N=35)

P value

Age

46.9±13.5

42.1±11.9

NS

Female gender

29 (78.4)

31 (88.6)

NS

Caucasian

23 (62.2)

24 (68.6)

NS

Time first manifestation (mo)

180 (96-240)

108 (69.5-192)

NS

aGAPSS

High aGAPSS (value≥10)

20 (54.1)

9 (25.7)

0.013

Hypertension

17 (45.9)

10 (28.6)

NS

Dyslipidemia

20 (54.1)

9 (25.7)

0.018

Lupus anticoagulant

34 (91.9)

32 (91.4)

NS

Anticardiolipin

15 (40.5)

13 (37.1)

NS

Anti-ß2-glycoprotein I

24 (64.9)

15 (42.9)

NS

Values showed as N(%) for categorical variables, Mean± SD for normal distribution and Median (interquartil range) for asymmetrical distribution.


Disclosure: F. Signorelli, None; G. G M Balbi, None; R. A. Levy, None; S. Sciascia, None.

To cite this abstract in AMA style:

Signorelli F, G M Balbi G, Levy RA, Sciascia S. Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/arterial-events-in-primary-antiphospholipid-syndrome-are-associated-with-high-values-of-the-adjusted-global-antiphospholipid-syndrome-score/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/arterial-events-in-primary-antiphospholipid-syndrome-are-associated-with-high-values-of-the-adjusted-global-antiphospholipid-syndrome-score/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology